PHAR Pharming Group N.V. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1828316 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $376.13M | $297.20M | $245.32M | $205.62M | $198.87M |
| Cost of revenue | $45.50M | $35.40M | $25.21M | $17.56M | $21.14M |
| Gross profit | $330.63M | $261.80M | $220.10M | $188.06M | $177.73M |
| R&D expense | $100.37M | $83.15M | $68.91M | $52.53M | $70.37M |
| SG&A expense | $79.96M | $70.65M | $55.88M | $46.02M | $36.97M |
| Operating income | $25.84M | -$8.62M | -$5.39M | $18.23M | $13.56M |
| Interest expense | $196,000 | $56,000 | $134,000 | $105,000 | $94,000 |
| Pretax income | $12.85M | -$8.49M | -$12.01M | $14.99M | $23.08M |
| Income tax | $10.31M | $3.35M | -$1.46M | $1.31M | $7.08M |
| Net income | $2.85M | -$11.84M | -$10.55M | $13.67M | $16.00M |
| EBITDA | — | — | — | — | $19.95M |
| EPS (basic) | 0.00 | -0.02 | -0.02 | 0.02 | 0.03 |
| EPS (diluted) | 0.00 | -0.02 | -0.02 | 0.02 | 0.02 |
| Weighted avg. shares (diluted) | 746.87M | 785.41M | 725.46M | 707.14M | 701.15M |
| Balance sheet | |||||
| Cash & equivalents | $145.31M | $54.94M | $61.74M | $207.34M | $191.92M |
| Receivables | $54.70M | $54.82M | $46.16M | $27.62M | $29.98M |
| Inventory | $64.90M | $55.72M | $56.76M | $42.33M | $27.31M |
| Current assets | $299.47M | $278.44M | $316.34M | $277.50M | $249.44M |
| PP&E, netmay include right-of-use assets (IFRS) | $7.23M | $7.75M | $9.69M | $10.39M | $13.22M |
| Intangibles | $135.54M | $61.04M | $71.27M | $75.12M | $83.83M |
| Total assets | $499.96M | $399.99M | $462.85M | $425.80M | $397.31M |
| Current liabilities | $115.79M | $73.80M | $77.97M | $59.70M | $46.77M |
| Total liabilities | $222.86M | $178.92M | $244.07M | $221.16M | $204.40M |
| Shareholders' equity | $277.10M | $221.06M | $218.78M | $204.64M | $192.92M |
| Shares outstanding | 701.68M | 680.31M | 671.07M | 656.35M | 648.75M |
| Cash flow statement | |||||
| Operating cash flow | $54.71M | -$1.79M | -$17.30M | $22.46M | $37.84M |
| Capital expenditure | $749,000 | $790,000 | $1.44M | $1.38M | $10.74M |
| Free cash flow | $53.96M | -$2.58M | -$18.74M | $21.08M | $27.10M |
| Investing cash flow | $26.25M | $31.62M | -$129.39M | $5.32M | -$21.30M |
| Financing cash flow | $1.50M | -$34.41M | -$1.04M | -$4.98M | -$27.95M |
| Depreciation & amortization | — | — | — | — | $6.39M |
| Stock-based compensation | $13.77M | $11.25M | $9.25M | $6.39M | $9.06M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.